Results 141 to 150 of about 36,964 (190)

Intermediate doses cytarabine after induction with CPX-351 for patients with secondary AML: safety and efficacy. [PDF]

Ann Hematol
Perrone S, Corbingi A, Vetro C, Palumbo FE, Minetto P, Riva C, Cicconi L, Vernarecci C, Lemoli RM, Pulsoni A, Guolo F.   +10 more
europepmc   +1 more source

Co-culture shock. [PDF]

Cell Death Discov
Behan JW, Mittelman SD.
europepmc   +1 more source

A Case of Acute Myelogenous Leukemia in Long-Term Remission After Severe Infection Following Only One Course of Chemotherapy. [PDF]

Case Rep Hematol
Shibusawa M.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Daunorubicin

Reactions Weekly, 2021
  +5 more sources

Daunorubicin and Platelet Function

Thrombosis and Haemostasis, 1981
SummaryThe influence of Daunorubicin on some platelet functions in vitro was investigated, using different concentrations of the drug (0.01-0.02-0.04 μg/ml). Daunorubicin was shown to inhibit Collagen and Thrombin induced platelet aggregation and the intensity of inhibition depended on both drug concentration and the time of preincubation.Daunorubicin ...
E M, Pogliani, R, Fantasia, G, Lambertenghi-Deliliers, E, Cofrancesco   +3 more
openaire   +2 more sources

Daunorubicin

Reactions Weekly, 2010
Ines Mader, Patrizia Fürst-Weger, Robert Mader, Elisabeth Nogler-Semenitz, Sabine Wassertheurer   +4 more
openaire   +2 more sources

Daunorubicin

Reactions Weekly, 1992
  +4 more sources

Daunorubicin

Reactions Weekly, 2002
Ines Mader, Patrizia E. Fürst-Weger, Robert M. Mader, Elisabeth I. Semenitz, Robert Terkola, Sabine M. Wassertheurer   +5 more
openaire   +2 more sources